Pancreatic Cancer Research

ResearcherSun Yat-sen UniversityActive in the last 2 years

Shangyou Zheng

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0009-0008-0528-9014; OpenAlex author ID A5102950377. Sources: OpenAlex.

Their work

Papers
38 (first author 1, last author 3)
Trials
0
Grants
0
Labs led
1
Collaborators
68
Papers, trials and grants by year

2015: 4 papers · 2016: 2 papers · 2017: 3 papers · 2018: 5 papers · 2019: 2 papers · 2020: 1 paper · 2021: 2 papers · 2022: 7 papers · 2023: 3 papers · 2024: 1 paper · 2025: 5 papers · 2026: 3 papers

Papers 38

  1. Cancer-associated fibroblasts drive gemcitabine resistance in pancreatic cancer by promoting ferroptosis resistance via the PAX6/PAK3/SLC3A2 axis. Last author DOI 10.1016/j.canlet.2026.218381↗
  2. circMTHFD1L-driven lipid metabolism in Cancer-associated fibroblasts confers oxaliplatin resistance in pancreatic cancer through O-GlcNAcylation-dependent chro… Co-author DOI 10.1016/j.canlet.2026.218863↗
  3. Lactylation-driven NSUN2-mediated RNA m5C modification promotes perineural invasion in pancreatic cancer. Last author DOI 10.7150/thno.122294↗
  4. Glycolysis reprogramming in CAFs promotes oxaliplatin resistance in pancreatic cancer through circABCC4 mediated PKM2 nuclear translocation. Co-author DOI 10.1038/s41419-025-07431-4↗
  5. Liver diseases, transaminases, and hepatobiliary-pancreatic cancer risk: a cohort and Mendelian randomisation study using data from UK Biobank. Co-author DOI 10.1136/bmjgast-2025-001870↗
  6. Cancer-Associated Fibroblasts Foster a High-Lactate Microenvironment to Drive Perineural Invasion in Pancreatic Cancer. Last author DOI 10.1158/0008-5472.can-24-3173↗
  7. Cancer-associated fibroblast-derived circKLHL24 drives perineural invasion in pancreatic cancer via dual regulation of the sec31a-CXCL12 axis. Co-author DOI 10.1186/s13046-025-03489-2↗
  8. Unexpected complete remission after recurrence in pancreatic cancer: a case report on comprehensive multimodal therapy. Co-author DOI 10.3389/fonc.2025.1582673↗
  9. Extracellular vesicle-packaged PIAT from cancer-associated fibroblasts drives neural remodeling by mediating m5C modification in pancreatic cancer mouse models. Co-author DOI 10.1126/scitranslmed.adi0178↗
  10. Mutant KRAS Mediates circARFGEF2 Biogenesis to Promote Lymphatic Metastasis of Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1158/0008-5472.can-22-3997↗
  11. Extracellular vesicle-packaged circBIRC6 from cancer-associated fibroblasts induce platinum resistance via SUMOylation modulation in pancreatic cancer. Co-author DOI 10.1186/s13046-023-02854-3↗
  12. HNF1A regulates oxaliplatin resistance in pancreatic cancer by targeting 53BP1. Co-author DOI 10.3892/ijo.2023.5493↗
  13. Corrigendum to "LncRNA HOTTIP modulates cancer stem cell properties in human pancreatic cancer by regulating HOXA9" [Canc. Lett. 410 (2017) 68-81]. Co-author DOI 10.1016/j.canlet.2022.215836↗
  14. Corrigendum to "Long non-coding RNA LOC389641 promotes progression of pancreatic ductal adenocarcinoma and increases cell invasion by regulating E-cadherin in … Co-author DOI 10.1016/j.canlet.2022.215859↗
  15. Corrigendum to "Macrophage-expressed CD51 promotes cancer stem cell properties via the TGF-β1/smad2/3 axis in pancreatic cancer" [Canc. Lett. 459(2019)204-215]. Co-author DOI 10.1016/j.canlet.2022.215897↗
  16. Cancer-associated fibroblast-induced lncRNA UPK1A-AS1 confers platinum resistance in pancreatic cancer via efficient double-strand break repair. First author DOI 10.1038/s41388-022-02253-6↗
  17. circFARP1 enables cancer-associated fibroblasts to promote gemcitabine resistance in pancreatic cancer via the LIF/STAT3 axis. Co-author DOI 10.1186/s12943-022-01501-3↗
  18. Correction: lncRNA-PLACT1 sustains activation of NF-κB pathway through a positive feedback loop with IκBα/E2F1 axis in pancreatic cancer. Co-author DOI 10.1186/s12943-022-01585-x↗
  19. circCUL2 induces an inflammatory CAF phenotype in pancreatic ductal adenocarcinoma via the activation of the MyD88-dependent NF-κB signaling pathway. Co-author DOI 10.1186/s13046-021-02237-6↗
  20. Correction: Cancer-associated fibroblasts promote progression and gemcitabine resistance via the SDF-1/SATB-1 pathway in pancreatic cancer. Co-author DOI 10.1038/s41419-021-03420-5↗
  21. A novel gene signature for prognosis prediction and chemotherapy response in patients with pancreatic cancer. Co-author DOI 10.18632/aging.202922↗
  22. lncRNA-PLACT1 sustains activation of NF-κB pathway through a positive feedback loop with IκBα/E2F1 axis in pancreatic cancer. Co-author DOI 10.1186/s12943-020-01153-1↗
  23. Macrophage-expressed CD51 promotes cancer stem cell properties via the TGF-β1/smad2/3 axis in pancreatic cancer. Co-author DOI 10.1016/j.canlet.2019.06.005↗
  24. Excessive miR-25-3p maturation via N6-methyladenosine stimulated by cigarette smoke promotes pancreatic cancer progression. Co-author DOI 10.1038/s41467-019-09712-x↗
  25. FEZF1-AS1/miR-107/ZNF312B axis facilitates progression and Warburg effect in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41419-017-0052-1↗
  26. Tumor-associated macrophages promote progression and the Warburg effect via CCL18/NF-kB/VCAM-1 pathway in pancreatic ductal adenocarcinoma. Co-author DOI 10.1038/s41419-018-0486-0↗
  27. Cancer-associated fibroblasts promote progression and gemcitabine resistance via the SDF-1/SATB-1 pathway in pancreatic cancer. Co-author DOI 10.1038/s41419-018-1104-x↗
  28. Linc00511 acts as a competing endogenous RNA to regulate VEGFA expression through sponging hsa-miR-29b-3p in pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/jcmm.13351↗
  29. Anticancer effect of HOTTIP regulates human pancreatic cancer via the metabotropic glutamate receptor 1 pathway. Co-author DOI 10.3892/ol.2018.8870↗
  30. LncRNA HOTTIP modulates cancer stem cell properties in human pancreatic cancer by regulating HOXA9. Co-author DOI 10.1016/j.canlet.2017.09.019↗
  31. Endogenous miRNA Sponge LincRNA-ROR promotes proliferation, invasion and stem cell-like phenotype of pancreatic cancer cells. Co-author DOI 10.1038/cddiscovery.2017.4↗
  32. HIF-2α regulates non-canonical glutamine metabolism via activation of PI3K/mTORC2 pathway in human pancreatic ductal adenocarcinoma. Co-author DOI 10.1111/jcmm.13202↗
  33. The long non-coding RNA HOTAIR affects the radiosensitivity of pancreatic ductal adenocarcinoma by regulating the expression of Wnt inhibitory factor 1. Co-author DOI 10.1007/s13277-015-4234-0↗
  34. Long non-coding RNA LOC389641 promotes progression of pancreatic ductal adenocarcinoma and increases cell invasion by regulating E-cadherin in a TNFRSF10A-rela… Co-author DOI 10.1016/j.canlet.2015.12.010↗
  35. Analysis of global gene expression profiles suggests a role of acute inflammation in type 3C diabetes mellitus caused by pancreatic ductal adenocarcinoma. Co-author DOI 10.1007/s00125-014-3481-8↗
  36. The long non-coding RNA HOTTIP promotes progression and gemcitabine resistance by regulating HOXA13 in pancreatic cancer. Co-author DOI 10.1186/s12967-015-0442-z↗
  37. High expression of AFAP1-AS1 is associated with poor survival and short-term recurrence in pancreatic ductal adenocarcinoma. Co-author DOI 10.1186/s12967-015-0490-4↗
  38. Expression profile of long non-coding RNAs in pancreatic cancer and their clinical significance as biomarkers. Co-author DOI 10.18632/oncotarget.5533↗

Closest collaborators

The 25 strongest of 68 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Rihua He · 12 shared papers, 2022–2026 · strength 2.48
  2. Chonghui Hu · 12 shared papers, 2019–2026 · strength 2.11
  3. Huimou Chen · 11 shared papers, 2015–2026 · strength 1.98
  4. Zhiqiang Fu · 19 shared papers, 2015–2026 · strength 1.88
  5. Quanbo Zhou · 19 shared papers, 2015–2022 · strength 1.69
  6. Huilin Ye · 18 shared papers, 2015–2022 · strength 1.49
  7. Zhihua Li · 11 shared papers, 2017–2026 · strength 1.47
  8. Rufu Chen · 15 shared papers, 2015–2022 · strength 1.39
  9. Guolin Li · 12 shared papers, 2016–2025 · strength 1.30
  10. Tianhao Huang · 5 shared papers, 2024–2026 · strength 1.14
  11. Rufu Chen · 5 shared papers, 2024–2026 · strength 1.11
  12. Chengyuan Hu · 5 shared papers, 2024–2025 · strength 1.11
  13. Changhao Chen · 9 shared papers, 2017–2024 · strength 1.07
  14. Yuming Luo · 8 shared papers, 2016–2023 · strength 0.87
  15. Rufu Chen · 8 shared papers, 2015–2023 · strength 0.84
  16. Yimin Liu · 12 shared papers, 2015–2022 · strength 0.83
  17. Rufu Chen · 4 shared papers, 2022–2025 · strength 0.79
  18. Renpeng Xia · 5 shared papers, 2022–2023 · strength 0.78
  19. Xiaohui Zhao · 11 shared papers, 2015–2022 · strength 0.74
  20. Lusheng Wei · 8 shared papers, 2017–2022 · strength 0.69
  21. Wenzhu Li · 8 shared papers, 2015–2022 · strength 0.52
  22. Xiang Zhang · 3 shared papers, 2021–2023 · strength 0.49
  23. Yong Jiang · 2 shared papers, 2025–2026 · strength 0.46
  24. Tingting Li · 2 shared papers, 2025 · strength 0.46
  25. Hongcao Lin · 3 shared papers, 2021–2022 · strength 0.45

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.